🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 101 of 173

  1. US 8858950

    Delivery of pharmaceutical agents via the human insulin receptor

    Expires Mon Oct 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8858945

    Three-dimensional structure of complement receptor type 2 and uses thereof

    Expires Mon Oct 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8852940

    Embryonic stem cell specific microRNAs promote induced pluripotency

    Expires Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8852568

    Compositions and methods for treating and preventing skeletal muscle deficiencies

    Expires Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8852447

    Porous nanostructures and methods involving the same

    Expires Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8853356

    Use of pentagastrin to inhibit gastric acid secretion or as a diuretic

    Expires Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8852626

    Controlled-release CNS modulating compositions and methods for the treatment of otic disorders

    Expires Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8853151

    Pro-drug complexes and related methods of use

    Expires Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8846629

    Id-1 and Id-2 genes and products as therapeutic targets for treatment of breast cancer and other types of carcinoma

    Expires Mon Sep 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8846066

    Methods and related compositions for reduction of fat and skin tightening

    Expires Mon Sep 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8846020

    Scaffolds formed from polymer-protein conjugates, methods of generating same and uses thereof

    Expires Mon Sep 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8845801

    Bone cement and method

    Expires Mon Sep 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8846006

    MRI markers, delivery and extraction systems, and methods of manufacture and use thereof

    Expires Mon Sep 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8846866

    Aldehyde tags, uses thereof in site-specific protein modification

    Expires Mon Sep 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8846859

    Compositions and methods of use of targeting peptides against placenta and adipose tissues

    Expires Mon Sep 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8846770

    Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders

    Expires Mon Sep 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8846697

    Purine analogs

    Expires Mon Sep 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8846684

    Arbovirus inhibitors and uses thereof

    Expires Mon Sep 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8846889

    Peptide biosynthesis and pain therapy

    Expires Mon Sep 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8846643

    Phosphonates with reduced toxicity for treatment of viral infections

    Expires Mon Sep 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8841258

    Methods to accelerate tissue and wound healing rates and reduce swelling and scar formation

    Expires Mon Sep 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8840868

    Non-invasive detection of complement-mediated inflammation using CR2-targeted nanoparticles

    Expires Mon Sep 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8840905

    Use of neurotoxin therapy for treatment of urologic and related disorders

    Expires Mon Sep 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8841350

    Method for inducing UDP-glucuronosyltransferase activity using pterostilbene

    Expires Mon Sep 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8841257

    Inhibitors of STAT3 and uses thereof

    Expires Mon Sep 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8841273

    Methods and compositions for anti-EGFR treatment

    Expires Mon Sep 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8835630

    Acyclic nucleoside phosphonate diesters

    Expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8835491

    Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance

    Expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8835493

    Oligo-benzamide compounds for use in treating cancers

    Expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8835386

    Activity of recombinant equine follicle stimulating hormone

    Expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8834938

    Use of arsenic for cancer therapy protection

    Expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8834896

    Vault compositions for immunization

    Expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8835166

    Extracellular matrix material created using non-thermal irreversible electroporation

    Expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8834871

    Immunoglobulin molecules with improved characteristics

    Expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8828980

    Controlled release corticosteroid compositions and methods for the treatment of otic disorders

    Expires Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8828383

    Nanocarriers with multi-photon response elements

    Expires Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8828652

    Elimination of N-glycolylneuraminic acid from animal products for human use

    Expires Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8828448

    Decellularisation of tissue matrices for bladder implantation

    Expires Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8821884

    Compositions and methods using MD-2 mutants and chimeric proteins

    Expires Mon Aug 28 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8822218

    Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts

    Expires Mon Aug 28 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8821943

    Methods and compositions for targeted delivery of therapeutic agents

    Expires Mon Aug 28 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8821899

    Method and process for the production of multi-coated recognitive and releasing systems

    Expires Mon Aug 28 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8815845

    1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties

    Expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8816151

    Stat5b transgenic mice and methods of use thereof

    Expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8815951

    Inhibitors of epoxide hydrolases for the treatment of inflammation

    Expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8815927

    Bivalent diazo bicyclic Smac mimetics and the uses thereof

    Expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8815830

    Nucleosides with antiviral and anticancer activity

    Expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8815212

    Nanocarriers for imaging and therapy applications

    Expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.